AES Completes First Phase of Largest Solar-Plus-Storage Project in the United States
Bellefield Project Highlights AES' Track Record of Working with Corporate Customers
ARLINGTON, Va., June 11, 2025 /PRNewswire/ -- The AES Corporation (NYSE: AES) today announced that it has completed construction of the 1,000 MW Bellefield 1 project, under a 15-year contract with Amazon. Bellefield is a two-phase project, with each phase including 500 MW of solar and 500 MW of four-hour battery-based energy storage, for a total of 2,000 MW of installed capacity. Once completed, the 2,000 MW Bellefield project is expected to be the largest solar-plus-storage facility in the United States.
"Completing the first 1,000 MW of Bellefield demonstrates how rapidly solar and storage can be deployed to meet the growing energy demand of data centers," said Andrés Gluski, AES President and Chief Executive Officer. "Our best-in-class track record of delivering renewables projects on time and on budget is deeply valued by our customers and is one of our key competitive advantages."
AES has been consistently recognized by Bloomberg New Energy Finance (BNEF) as a top provider of clean energy to corporations, including technology companies. AES has contractual arrangements with major global hyperscalers for 10.1 GW, including the 2 GW Bellefield project.
To accelerate Bellefield's implementation and ensure system reliability, AES utilized Maximo, an AI-enabled robotic system developed by AES to assist construction crews, improving the safety, speed, and accuracy of solar module installation.
The 2 GW Bellefield project, located in Kern County, California, will generate equivalent to the annual electricity usage of 467,000 homes, displacing over 1 million metric tons of CO₂ annually, and improving air quality. More than 700 union jobs were created during the construction of Bellefield 1 and approximately 1,000 union jobs are expected to be created at the peak of construction of Bellefield 2, further supporting local businesses.
The Company expects to recognize the significant earnings associated with placing Bellefield 1 in service in the second half of this year, as planned. Construction on Bellefield 2 is on track to be completed in 2026.
About AES
The AES Corporation (NYSE: AES) is a Fortune 500 global energy company accelerating the future of energy. Together with our many stakeholders, we're improving lives by delivering the greener, smarter energy solutions the world needs. Our diverse workforce is committed to continuous innovation and operational excellence, while partnering with our customers on their strategic energy transitions and continuing to meet their energy needs today. For more information, visit www.aes.com.
Safe Harbor Disclosure
This news release contains forward-looking statements within the meaning of the Securities Act of 1933 and of the Securities Exchange Act of 1934. Such forward-looking statements include, but are not limited to, those related to future earnings, growth and financial and operating performance. Forward-looking statements are not intended to be a guarantee of future results, but instead constitute AES' current expectations based on reasonable assumptions. Forecasted financial information is based on certain material assumptions. These assumptions include, but are not limited to, our expectations regarding accurate projections of future interest rates, commodity price and foreign currency pricing, continued normal levels of operating performance and electricity volume at our distribution companies and operational performance at our generation businesses consistent with historical levels, as well as the execution of PPAs, conversion of our backlog and growth investments at normalized investment levels, and rates of return consistent with prior experience.
Actual results could differ materially from those projected in our forward-looking statements due to risks, uncertainties and other factors. Important factors that could affect actual results are discussed in AES' filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, the risks discussed under Item 1A: "Risk Factors" and Item 7: "Management's Discussion & Analysis" in AES' 2024 Annual Report on Form 10-K and in subsequent reports filed with the SEC. Readers are encouraged to read AES' filings to learn more about the risk factors associated with AES' business. AES undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except where required by law.
Any Stockholder who desires a copy of the Company's 2024 Annual Report on Form 10-K filed March 11, 2025 with the SEC may obtain a copy (excluding the exhibits thereto) without charge by addressing a request to the Office of the Corporate Secretary, The AES Corporation, 4300 Wilson Boulevard, Arlington, Virginia 22203. Exhibits also may be requested, but a charge equal to the reproduction cost thereof will be made. A copy of the Annual Report on Form 10-K may be obtained by visiting the Company's website at www.aes.com.
Website Disclosure
AES uses its website, including its quarterly updates, as channels of distribution of Company information. The information AES posts through these channels may be deemed material. Accordingly, investors should monitor our website, in addition to following AES' press releases, quarterly SEC filings and public conference calls and webcasts. In addition, you may automatically receive e-mail alerts and other information about AES when you enroll your e-mail address by visiting the "Subscribe to Alerts" page of AES' Investors website. The contents of AES' website, including its quarterly updates, are not, however, incorporated by reference into this release.
Press Release
Investor Contact: Susan Harcourt 703-682-1204, susan.harcourt@aes.com
Media Contact: Katie Lau 571-286-9362, katie.lau@aes.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/aes-completes-first-phase-of-largest-solar-plus-storage-project-in-the-united-states-302478336.html
SOURCE The AES Corporation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Popular stock crashes 20% in a day after surprising news
Popular stock crashes 20% in a day after surprising news originally appeared on TheStreet. GameStop's (NYSE: GME) stock price declined 20.98% in the past 24 hours, following the announcement of its plan to offer $1.75 billion in convertible senior secured notes. These notes are convertible, meaning the debt can be later converted into shares of the company's stock. GameStop announced in March that it would adopt a new business model, which included making investments in "Bitcoin as a treasury reserve asset." As per Fortune, the company did not specify Bitcoin as a reason for raising the capital. Still, it stated on Wednesday that the money would enable it to accelerate its transformation further as it seeks to create value in the video game industry through upgrades to its e-commerce capabilities and infrastructure, further developing its U.S. distribution network, and hiring talent to support growth and drive its product offerings. GameStop was trading at $22.38 at the time of writing, a fall of 36% from its 52-week high of $35.01 in May 2025. The sell-off has occurred despite the company beating Wall Street's estimates for both gross margin and earnings per share, while also reporting positive free cash flow. This update, however, came as part of a more extended slump across the broader set of crypto markets. According to Kraken's price feed, Bitcoin fell 2% to approximately $107,560 as traders took profits and responded to warnings of a potential correction. Although GameStop's Bitcoin play is a sign of a strategic pivot to alternative assets, it was insufficient to assuage markets regarding the long-term viability of its core retail business. The firm also stated that first-quarter sales declined 17% due to weak demand for gaming hardware and software. Popular stock crashes 20% in a day after surprising news first appeared on TheStreet on Jun 12, 2025 This story was originally reported by TheStreet on Jun 12, 2025, where it first appeared. Sign in to access your portfolio
Yahoo
12 minutes ago
- Yahoo
Cancer Pain Market Set to Transform by 2034 Due to Launch of Breakthrough Therapies
According to DelveInsight's analysis, the growth of the cancer pain market is expected to be mainly driven by increasing incidence and advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more drug development. The market is expected to show positive growth, mainly attributed to the increasing cases and also, the launch of upcoming therapies during the forecast period. LAS VEGAS, June 12, 2025 /PRNewswire/ -- DelveInsight's Cancer Pain Market Insights report includes a comprehensive understanding of current treatment practices, cancer pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Cancer Pain Market Report According to DelveInsight's analysis, the market size for cancer pain is expected to rise at a significant CAGR by 2034. The United States is expected to account for the highest market size of cancer pain, of the total market size in 7MM in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. According to DelveInsight's analysis, the total cancer pain cases in 2023 for the US were 2.4 million. In 2023, based on the pathophysiology of cancer pain, nociceptive pain accounted for the highest number of cases in the US. Leading cancer pain companies developing emerging therapies, such as InhaleRX, Dogwood Therapeutics, WinSanTor, AlgoTherapeutix, Artelo Biosciences, Asahi Kasei Pharma, and others, are developing novel cancer pain drugs that can be available in the cancer pain market in the coming years. The promising cancer pain therapies in the pipeline include IRX211, HALNEURON (tetrodotoxin), WST-057, ATX01, ART26.12, ART-123, and others. Discover which therapies are expected to grab the major cancer pain market share @ Cancer Pain Market Report Cancer Pain Overview Cancer pain is a common and often debilitating symptom experienced by individuals with cancer, resulting from a variety of causes such as tumor invasion into surrounding tissues, inflammation, nerve compression, or the side effects of treatments like chemotherapy, radiation, and surgery. The nature of cancer pain can vary significantly, it may be acute or chronic, localized or widespread, and described as dull, sharp, burning, or throbbing. Pain not only affects a patient's physical functioning but also takes a toll on emotional well-being, often leading to anxiety, depression, and sleep disturbances. Effective pain management is crucial to maintaining quality of life and supporting overall treatment goals. Cancer Pain Epidemiology Segmentation The cancer pain epidemiology section provides insights into the historical and current cancer pain patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The cancer pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Cases of Cancer Pain Etiology-specific Cases of Cancer Pain Incident Cases of Chemotherapy-Induced Peripheral Neuropathy Severity-specific Cases of Cancer Pain Pathophysiology-specific Cases of Cancer Pain Temporal Variation-specific Cases of Cancer Pain Incident Cases of Breakthrough Cancer Pain (BTcP) Cancer Pain Treatment Market Managing chronic cancer-related pain should be personalized, balancing the benefits and drawbacks within the broader context of the patient's overall care goals. When planning pain management, it's important to consider whether disease-modifying treatments are feasible, appropriate, and how they might impact pain. If the pain is localized and caused by tumor pressure or destruction, such as bone lesions, radiotherapy can be very effective. Regardless of whether primary treatments are possible, many patients with active disease-related pain will still require symptom-focused therapies. A thorough pain evaluation is essential to develop a comprehensive, multimodal treatment plan. The first step is to set realistic expectations for the patient, since the cause of the pain affects the likely improvement in pain levels and daily functioning. Patients can be offered various treatment options, including over-the-counter pain relievers, non-opioid prescriptions, procedural interventions, complementary therapies, and systemic opioids. For moderate to severe cancer pain, opioids remain the cornerstone of treatment. Long-term opioid use aims to achieve consistent, meaningful pain relief with manageable side effects, ultimately improving quality of life. Pure μ-opioid receptor agonists are generally preferred for cancer pain, except for drugs like pethidine and dextropropoxyphene, which are discouraged due to their risk of adverse effects. While partial agonists like buprenorphine and mixed-mechanism drugs such as tramadol and tapentadol are options, pure μ-agonists are more commonly used and allow for more flexible dosing. Patients have access to various non-opioid treatment options, which include both medication-based and non-medication approaches. Acetaminophen is often used as a first-choice therapy for patients experiencing mild cancer pain who either do not need opioids or prefer to avoid them. It can also be combined with opioids, and some prescribed medications include both acetaminophen and an opioid in a single tablet for convenience. However, its use in cancer patients is limited due to the risk of liver toxicity, especially in those with liver conditions, and requires careful monitoring for fever in patients with neutropenia. To know more about cancer pain treatment guidelines, visit @ Cancer Pain Management Cancer Pain Pipeline Therapies and Key Companies IRX211: InhaleRX HALNEURON (tetrodotoxin): Dogwood Therapeutics WST-057: WinSanTor ATX01: AlgoTherapeutix ART26.12: Artelo Biosciences ART-123: Asahi Kasei Pharma Discover more about cancer pain drugs in development @ Cancer Pain Clinical Trials Cancer Pain Market Dynamics The cancer pain market dynamics are expected to change in the coming years. The increasing global prevalence of cancer and rising awareness of cancer-associated pain are expected to drive growth in the cancer pain therapeutics market. With no recent drug approvals in this space, pharmaceutical companies have a significant opportunity to penetrate the market, particularly by developing nonopioid-based treatments. As opioids continue to dominate cancer pain management, the anticipated launch of drugs like tetrodotoxin signals a major shift toward novel, nonopioid mechanisms, highlighting the vast potential for innovation in this therapeutic area. Furthermore, potential therapies are being investigated for the treatment of cancer pain, and it is safe to predict that the treatment space will significantly impact the cancer pain market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the cancer pain market in the 7MM. However, several factors may impede the growth of the cancer pain market. Poor assessment of pain, inadequate clinician knowledge, lack of coverage and uneven healthcare reimbursement policies, and the limited effectiveness of standard pain medications such as opioids in cases of refractory pain have all been identified as major barriers to effective cancer pain management, underscoring the need to improve understanding of pain and leverage that knowledge to develop new and more effective treatments. Moreover, cancer pain treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the cancer pain market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the cancer pain market growth. Cancer Pain Market Report Metrics Details Study Period 2020–2034 Coverage 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Cancer Pain Companies InhaleRX, Dogwood Therapeutics, WinSanTor, AlgoTherapeutix, Artelo Biosciences, Asahi Kasei Pharma, and others Key Pipeline Cancer Pain Therapies IRX211, HALNEURON (tetrodotoxin), WST-057, ATX01, ART26.12, ART-123, and others Scope of the Cancer Pain Market Report Therapeutic Assessment: Cancer Pain current marketed and emerging therapies Cancer Pain Market Dynamics: Key Market Forecast Assumptions of Emerging Cancer Pain Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Cancer Pain Market Access and Reimbursement Download the report to understand which factors are driving cancer pain market trends @ Cancer Pain Market Trends Table of Contents 1. Cancer Pain Market Key Insights 2. Cancer Pain Market Report Introduction 3. Cancer Pain Market Overview at a Glance 4. Cancer Pain Market Executive Summary 5. Disease Background and Overview 6. Cancer Pain Treatment and Management 7. Cancer Pain Epidemiology and Patient Population 8. Patient Journey 9. Cancer Pain Marketed Drugs 10. Cancer Pain Emerging Drugs 11. Seven Major Cancer Pain Market Analysis 12. Cancer Pain Market Outlook 13. Potential of Current and Emerging Therapies 14. KOL Views 15. Unmet Needs 16. SWOT Analysis 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight Related Reports Cancer Pain Epidemiology Forecast Cancer Pain Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the cancer pain epidemiology trends. Advanced Cancer Pain Management Pipeline Advanced Cancer Pain Management Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced cancer pain management companies, including Tetra Bio-Pharma, ZYUS Life Sciences, among others. Advanced Cancer Pain Management Market Advanced Cancer Pain Management Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced cancer pain management companies, including Tetra Bio-Pharma, ZYUS Life Sciences, among others. Cancer Supportive Care Drugs Market Cancer Supportive Care Drugs Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key cancer supportive care drugs companies, including Helsinn Healthcare SA, Merck & Co., Inc., Sanofi, Pfizer Inc., GSK plc, F. Hoffmann-La Roche Ltd., Amgen Inc., Novartis AG, Viatris Inc., Nimbus Therapeutics, Gilead Sciences, Inc., Eli Lilly and Company, Moderna, Inc., AbbVie Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Otsuka Holdings Co., Ltd., Affimed GmbH, Bristol-Myers Squibb Company, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ + Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
16 minutes ago
- Business Wire
Hercules Capital Renews and Increases Its Credit Facility with MUFG Bank, Ltd. to $440.0 Million
SAN MATEO, Calif.--(BUSINESS WIRE)-- Hercules Capital, Inc. (NYSE: HTGC) ('Hercules' or the 'Company'), the largest and leading specialty finance provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has upsized and renewed its existing $400.0 million credit facility with MUFG Bank, Ltd. ('MUFG') with an upsized credit facility under which Goldman Sachs Bank USA, Autobahn Funding Company LLC, City National Bank, a National Banking Association, Umpqua Bank, Valley National Bank, Citizens Bank, N.A., Zions Bancorporation, N.A., dba California Bank & Trust and Mitsubishi HC Capital America, Inc. together with MUFG, have committed a total of $440.0 million in credit capacity subject to borrowing base, leverage and other restrictions. The upsized and renewed credit facility continues to include an uncommitted accordion feature expandable up to $600.0 million. The renewed credit facility matures in June 2029. 'The renewal and increase of our credit facility with MUFG will further support the growth of our business and allow us to take advantage of our current and future market opportunities,' said Seth Meyer, chief financial officer of Hercules. 'We welcome the new lenders to the group and thank our existing bank partners for their support of our industry-leading franchise and look forward to continuing our long-term relationship.' For additional information, please review the Company's current report on Form 8-K, to be filed with the Securities and Exchange Commission ('SEC'). About Hercules Capital, Inc. Hercules Capital, Inc. (NYSE: HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology and life sciences industries. Since inception (December 2003), Hercules has committed more than $22 billion to over 680 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. Companies interested in learning more about financing opportunities should contact info@ or call (650) 289-3060. Hercules, through its wholly owned subsidiary business, Hercules Adviser LLC (the 'Adviser Subsidiary'), also maintains an asset management business through which it manages investments for external parties ('Adviser Funds'). The Adviser Subsidiary is registered as an investment adviser under the Investment Advisers Act of 1940. Hercules' common stock trades on the New York Stock Exchange (NYSE) under the ticker symbol 'HTGC.' In addition, Hercules has one retail bond issuance of 6.25% Notes due 2033 (NYSE: HCXY). Forward-Looking Statements This press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. We may use words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'will,' 'should,' 'may' and similar expressions to identify forward-looking statements. Forward-looking statements are not guarantees of future performance and should not be relied upon in making any investment decision. Such statements are based on currently available operating, financial and competitive information and are subject to various risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations. While we cannot identify all such risks and uncertainties, we urge you to read the risks discussed in our Annual Report on Form 10-K and other materials that we publicly file with the Securities and Exchange Commission. Any forward-looking statements made in this press release are made only as of the date hereof. Hercules assumes no obligation to update any such statements in the future.
